Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study
Anti-T2 biological therapies have proven to effectively reduce acute exacerbations and daily doses of oral steroids in severe eosinophilic asthma. Despite the remarkable clinical efficacy, there are usually only moderate improvements in airflow limitation, suggesting that other measures of lung func...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
21 October 2020
|
| In: |
Respiratory research
Year: 2020, Volume: 21 |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-020-01543-5 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12931-020-01543-5
|
| Author Notes: | Mustafa Abdo, Henrik Watz, Vera Veith, Anne-Marie Kirsten, Heike Biller, Frauke Pedersen, Erika von Mutius, Matthias V. Kopp, Gesine Hansen, Benjamin Waschki, Klaus F. Rabe, Frederik Trinkmann and Thomas Bahmer |
| Summary: | Anti-T2 biological therapies have proven to effectively reduce acute exacerbations and daily doses of oral steroids in severe eosinophilic asthma. Despite the remarkable clinical efficacy, there are usually only moderate improvements in airflow limitation, suggesting that other measures of lung function like small airway dysfunction (SAD) might better reflect the clinical response. We aimed to investigate if measures of small airway function would predict and correlate with the clinical response to anti-T2 therapy. |
|---|---|
| Item Description: | Gesehen am 26.11.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-020-01543-5 |